Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on April 13, 2009. The filing discloses executive management changes effective May 15, 2009, specifically regarding the appointment of a new Chief Financial Officer and the reassignment of the current CFO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation arrangements rather than financial performance data.
Material Changes
- Executive Appointment: Kurt A. Gustafson will assume the position of Chief Financial Officer (CFO), succeeding David A. Ramsay.
- Executive Reassignment: David A. Ramsay will transition from CFO to Vice President, Corporate Development.
- Compensation: Mr. Gustafson's annual salary is set at $300,000. He is eligible for the 2009 senior executive incentive plan and standard employee benefits.
- Equity Grant: Mr. Gustafson received a stock option grant for 200,000 shares of common stock. Vesting terms include 25% on the one-year anniversary, with the remainder vesting monthly over the subsequent three years.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The document is limited to the disclosure of the officer appointment and associated biographical details.
Investor Verification Checklist
- Verify the effective date of the leadership transition (May 15, 2009).
- Confirm the vesting schedule details for the 200,000 share option grant to the new CFO.
- Review the company's 2009 senior executive incentive plan to understand potential variable compensation.
- Assess the strategic implications of the current CFO moving to Corporate Development.